Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients

Kevin T. Savage; Monica Rosales Santillan; Kelsey S. Flood; Alexandra Charrow; Martina L. Porter; Alexa B. Kimball

doi:10.1016/j.jdcr.2019.10.010

Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients

Kevin T. Savage, Monica Rosales Santillan, Kelsey S. Flood, Alexandra Charrow, Martina L. Porter, Alexa B. Kimball^*

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Original language	English (US)
Pages (from-to)	99-102
Number of pages	4
Journal	JAAD Case Reports
Volume	6
Issue number	2
DOIs	https://doi.org/10.1016/j.jdcr.2019.10.010
State	Published - Feb 2020

Funding

Conflicts of interest: Dr Alexa B. Kimball serves as a consultant and investigator for Novartis, Abbvie, UCB, Janssen, and Pfizer. Her fellowship program receives funding from Janssen and Abbvie. Dr Martina Porter serves as a consultant to AbbVie and Novartis. Dr Kelsey Flood has received fellowship funding from AbbVie and Janssen that went directly to her institution. Dr Monica Rosales Santillan has received fellowship funding from AbbVie and Janssen that went directly to her institution. Mr Savage and Dr Charrow have no conflicts to disclose.

Keywords

hidradenitis suppurativa
phenotype
tofacitinib
treatment
ulceration

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jdcr.2019.10.010

Cite this

@article{e3365ba54f154736b64237eeeea04dba,

title = "Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients",

keywords = "hidradenitis suppurativa, phenotype, tofacitinib, treatment, ulceration",

author = "Savage, {Kevin T.} and Santillan, {Monica Rosales} and Flood, {Kelsey S.} and Alexandra Charrow and Porter, {Martina L.} and Kimball, {Alexa B.}",

note = "Funding Information: Conflicts of interest: Dr Alexa B. Kimball serves as a consultant and investigator for Novartis, Abbvie, UCB, Janssen, and Pfizer. Her fellowship program receives funding from Janssen and Abbvie. Dr Martina Porter serves as a consultant to AbbVie and Novartis. Dr Kelsey Flood has received fellowship funding from AbbVie and Janssen that went directly to her institution. Dr Monica Rosales Santillan has received fellowship funding from AbbVie and Janssen that went directly to her institution. Mr Savage and Dr Charrow have no conflicts to disclose.",

year = "2020",

month = feb,

doi = "10.1016/j.jdcr.2019.10.010",

language = "English (US)",

volume = "6",

pages = "99--102",

journal = "JAAD Case Reports",

issn = "2352-5126",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients

AU - Savage, Kevin T.

AU - Santillan, Monica Rosales

AU - Flood, Kelsey S.

AU - Charrow, Alexandra

AU - Porter, Martina L.

AU - Kimball, Alexa B.

N1 - Funding Information: Conflicts of interest: Dr Alexa B. Kimball serves as a consultant and investigator for Novartis, Abbvie, UCB, Janssen, and Pfizer. Her fellowship program receives funding from Janssen and Abbvie. Dr Martina Porter serves as a consultant to AbbVie and Novartis. Dr Kelsey Flood has received fellowship funding from AbbVie and Janssen that went directly to her institution. Dr Monica Rosales Santillan has received fellowship funding from AbbVie and Janssen that went directly to her institution. Mr Savage and Dr Charrow have no conflicts to disclose.

PY - 2020/2

Y1 - 2020/2

KW - hidradenitis suppurativa

KW - phenotype

KW - tofacitinib

KW - treatment

KW - ulceration

UR - http://www.scopus.com/inward/record.url?scp=85078507853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078507853&partnerID=8YFLogxK

U2 - 10.1016/j.jdcr.2019.10.010

DO - 10.1016/j.jdcr.2019.10.010

M3 - Article

C2 - 31993474

AN - SCOPUS:85078507853

SN - 2352-5126

VL - 6

SP - 99

EP - 102

JO - JAAD Case Reports

JF - JAAD Case Reports

IS - 2

ER -

Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this